The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...

Shares of BioArctic AB (STO:BIOA B) climbed 4.8% following the announcement of its partner Eisai's robust sales figures for ...

In the latest development, the European Commission has asked the EMA's human medicines committee, the CHMP, to take a look at ...

The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing for Leqembi (lecanemab), a treatment for early Alzheimer’s disease.

Citi analysts adjusted their outlook on Eisai Co Ltd (OTC:ESAIY). (4523:JP) (OTC: ESALY), reducing the price target from JPY6,000 to JPY5,000, while continuing to endorse the stock with a Buy rating.

Bernstein initiated coverage of Biogen (BIIB) with a Market Perform rating and $160 price target For the past five years, Biogen “has lived ...

The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.

The U.S. Food and Drug Administration approved Eisai and Biogen’s application for IV maintenance dosing of lecanemab on January 27. Previously, the label called for biweekly IV dosing. The new ...

Key contributors included LEQEMBI with a 28.1 billion yen increase, Lenvima with 24.9 billion yen growth, and Dayvigo up by 9.3 billion yen. Naito emphasized significant milestones for LEQEMBI ...

EMA approval of the Alzheimer’s disease therapy Leqembi (lecanemab) has stalled once again, after the European Commission did not as usual nod through the agency’s recommendation, but told it to ...

These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today issued their quarterly report containing Leqembi sales for the fourth quarter 2024 (third quarter ...